News Lilly says 2026 looks good, as sales rocket in Q4 Eli Lilly is predicting strong sales and profit growth in 2026, seemingly shrugging off the pricing pressure that weighed heavily on Novo Nordisk.
News GSK delivers in new CEO Miels' first financial update Luke Miels' first financial results since taking over as chief executive of GSK revealed a jump in sales and profits.
News Novo Nordisk slumps on tougher 2026 financial outlook Squeezed by "unprecedented" pricing pressures, Novo Nordisk has forecast a decline in revenues this year.
News Patent losses hit Novartis hard, but CEO has a plan Novartis CEO Vas Narasimhan says the company is equipped to ride out "the largest patent expiry" in its history," but 2026 will still be tricky.
News Andexxa reaches the end of the line in the US AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US amid reports of serious clotting side effects.
News Setback for MSD as German court blocks Keytruda SC launch A court in Germany has granted an injunction that will prevent MSD from distributing the new, subcutaneous version of its cancer drug Keytruda.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.